- Home
- FRD vs ELTX Comparison
FRD vs ELTX Comparison
Compare FRD & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | ELTX |
|---|---|---|
| Founded | 1965 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 134.1M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRD | ELTX |
|---|---|---|
| Price | $18.33 | $9.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 21.8K | ★ 129.1K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 38.94 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $12.24 | $4.60 |
| 52 Week High | $24.37 | $12.62 |
Technical Indicators
Market Signals| Indicator | FRD | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 58.99 |
| Support Level | $18.54 | $8.76 |
| Resistance Level | $20.60 | $9.25 |
| Average True Range (ATR) | 1.19 | 0.72 |
| MACD | -0.19 | 0.08 |
| Stochastic Oscillator | 12.89 | 68.90 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.